Skip to main content
Caplight Logo









Esperovax

Esperovax

Private
Plymouth, MichiganHealthcare & Life Scienceshttps://esperovax.com/

Last Round

Grant

Dec 12, 2024

Total Funding Raised

$3.41M

Company Overview

Esperovax is a biotechnology company that has developed a novel mRNA oral vaccine platform to enable large-scale production and distribution of shelf-stable vaccines.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Defense Tech

Business Model

B2G

Customer Profile

Government Contracts, Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

oral mRNA vaccinesoral biologics platformyeast-based deliverythermostable vaccinesvaccine pillmRNA delivery platformoral vaccinebiodefenseshelf-stable vaccinesmucosal immunitybiothreat countermeasuresRNA pillcold-chain freeplatform licensingpreclinical development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Esperovax Comparables

Compare Esperovax with similar companies based on industry and business-model similarity.

Esperovax comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Fzata, Inc.
82%
iosBio
79%
GIVAX
75%

Esperovax Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 12, 2024
GrantAug 23, 2023
SeedApr 29, 2021
Convertible DebtApr 9, 2021
Convertible DebtJan 19, 2021
Grant
Sep 23, 2020

Esperovax Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 24, 2026

    Monthly visitors grew 80% MoM, from 670 to 1.2K.

  • May 1, 2025

    Monthly visitors increased 907% to 1.4K.

Esperovax Filings

Explore SEC and related filing metadata, where available.

Esperovax filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Esperovax's valuation, stock price, and market status.

Is Esperovax a public or private company?

Esperovax is a private company.

What is the current stock price of Esperovax?

Esperovax is a private company with no public stock price. No recent secondary market data is available.

How much is Esperovax worth (valuation)?

Valuation information for Esperovax is not publicly available.

Can I buy Esperovax stock?

Esperovax shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Esperovax's last funding round?

Funding round information for Esperovax is not publicly available.

Who are the main investors in Esperovax?

Investor information for Esperovax is not publicly disclosed.

Will Esperovax IPO soon?

No public IPO plans have been announced for Esperovax.

How can I track Esperovax secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Esperovax's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPlymouth, Michigan
Employee Range1
Year Founded2018
Last FundingDec 12, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?